Do analysts recommend BLRX or INCR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BLRX or INCR more profitable?

InterCure has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. InterCure's return on equity of 0.00% beat BioLineRx's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% InterCure N/A N/A N/A

Does the media prefer BLRX or INCR?

In the previous week, InterCure had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for InterCure and 1 mentions for BioLineRx. InterCure's average media sentiment score of 1.00 beat BioLineRx's score of 0.00 indicating that InterCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InterCure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate IMMP or BLRX?

Prima BioMed currently has a consensus target price of $5.50, suggesting a potential upside of 1,318.26%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, IMMP or BLRX?

BioLineRx has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.54 -$39.78M N/A N/A BioLineRx $1.18M 12.48 -$1.17M -$1.92 N/A

Does the media favor IMMP or BLRX?

In the previous week, Prima BioMed had 6 more articles in the media than BioLineRx. MarketBeat recorded 7 mentions for Prima BioMed and 1 mentions for BioLineRx. Prima BioMed's average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BLRX or TIL?

Instil Bio has a consensus price target of $66.00, suggesting a potential upside of 763.87%. Given Instil Bio's stronger consensus rating and higher possible upside, analysts plainly believe Instil Bio is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BLRX or TIL more profitable?

Instil Bio has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% Instil Bio N/A -39.76% -22.38%

Do analysts recommend AADI or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BLRX or DWTX?

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 694.70%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

BioLineRx (BLRX) Competitors

$3.37 +0.11 (+3.37%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$3.20 -0.17 (-5.16%)

As of 06/24/2026 06:34 PM Eastern

Compare

BLRX vs. INCR, IMMP, TIL, AADI, and DWTX

Should you buy BioLineRx stock or one of its competitors? MarketBeat compares BioLineRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLineRx include InterCure (INCR), Prima BioMed (IMMP), Instil Bio (TIL), Aadi Bioscience (AADI), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry.

How does BioLineRx compare to InterCure?

BioLineRx (NASDAQ:BLRX) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

BioLineRx has higher earnings, but lower revenue than InterCure. BioLineRx is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	12.48	-$1.17M	-$1.92	N/A
InterCure	$78.47M	0.70	-$10.37M	$0.03	33.33

InterCure has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. InterCure's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
InterCure	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioLineRx has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, InterCure has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, InterCure had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for InterCure and 1 mentions for BioLineRx. InterCure's average media sentiment score of 1.00 beat BioLineRx's score of 0.00 indicating that InterCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InterCure	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InterCure beats BioLineRx on 9 of the 13 factors compared between the two stocks.

How does BioLineRx compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Prima BioMed currently has a consensus target price of $5.50, suggesting a potential upside of 1,318.26%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Prima BioMed has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

Prima BioMed has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. Prima BioMed's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
BioLineRx	-563.70%	-37.73%	-19.42%

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioLineRx has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.54	-$39.78M	N/A	N/A
BioLineRx	$1.18M	12.48	-$1.17M	-$1.92	N/A

In the previous week, Prima BioMed had 6 more articles in the media than BioLineRx. MarketBeat recorded 7 mentions for Prima BioMed and 1 mentions for BioLineRx. Prima BioMed's average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Prima BioMed beats BioLineRx on 11 of the 13 factors compared between the two stocks.

How does BioLineRx compare to Instil Bio?

BioLineRx (NASDAQ:BLRX) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, BioLineRx had 1 more articles in the media than Instil Bio. MarketBeat recorded 1 mentions for BioLineRx and 0 mentions for Instil Bio. BioLineRx's average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
BioLineRx	Neutral
Instil Bio	Neutral

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 47.0% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Instil Bio has a consensus price target of $66.00, suggesting a potential upside of 763.87%. Given Instil Bio's stronger consensus rating and higher possible upside, analysts plainly believe Instil Bio is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Instil Bio has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Instil Bio	N/A	-39.76%	-22.38%

BioLineRx has higher revenue and earnings than Instil Bio. BioLineRx is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	12.48	-$1.17M	-$1.92	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

BioLineRx has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

Summary

Instil Bio beats BioLineRx on 7 of the 13 factors compared between the two stocks.

How does BioLineRx compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, BioLineRx had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for BioLineRx and 0 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
BioLineRx	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

Aadi Bioscience has a net margin of -246.06% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
BioLineRx	-563.70%	-37.73%	-19.42%

BioLineRx has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.30	-$65.76M	-$2.35	N/A
BioLineRx	$1.18M	12.48	-$1.17M	-$1.92	N/A

Summary

BioLineRx beats Aadi Bioscience on 9 of the 13 factors compared between the two stocks.

How does BioLineRx compare to Dogwood Therapeutics?

BioLineRx (NASDAQ:BLRX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 694.70%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dogwood Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

BioLineRx has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

In the previous week, BioLineRx had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 1 mentions for BioLineRx and 0 mentions for Dogwood Therapeutics. BioLineRx's average media sentiment score of 0.00 equaled Dogwood Therapeutics'average media sentiment score.

Company	Overall Sentiment
BioLineRx	Neutral
Dogwood Therapeutics	Neutral

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BioLineRx has higher revenue and earnings than Dogwood Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	12.48	-$1.17M	-$1.92	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Summary

BioLineRx and Dogwood Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLRX vs. The Competition

Export

Metric	BioLineRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.24M	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	-1.76	18.65	25.37	23.95
Price / Sales	12.48	341.96	530.17	107.90
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	0.63	4.14	10.76	6.41
Net Income	-$1.17M	$64.45M	$3.56B	$337.14M
7 Day Performance	6.65%	1.22%	0.99%	-1.06%
1 Month Performance	10.13%	0.95%	0.79%	0.49%
1 Year Performance	-24.94%	25.22%	30.25%	28.43%

BioLineRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLRX BioLineRx	0.2934 of 5 stars	$3.37 +3.4%	N/A	-24.1%	$14.24M	$1.18M	N/A	40
INCR InterCure	1.4048 of 5 stars	$0.96 +0.5%	N/A	-33.8%	$52.49M	$78.47M	32.00	350	Gap Down
IMMP Prima BioMed	1.8617 of 5 stars	$0.36 -3.8%	$5.50 +1,444.1%	-75.8%	$52.49M	$6.69M	N/A	2,021
TIL Instil Bio	1.512 of 5 stars	$7.61 -3.9%	$66.00 +767.3%	-73.2%	$51.60M	N/A	N/A	410
AADI Aadi Bioscience	N/A	$4.10 -1.4%	N/A	+124.1%	$50.63M	$25.07M	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLRX) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLineRx (BLRX) Competitors

BLRX vs. INCR, IMMP, TIL, AADI, and DWTX

How does BioLineRx compare to InterCure?

Summary

How does BioLineRx compare to Prima BioMed?

Summary

How does BioLineRx compare to Instil Bio?

Summary

How does BioLineRx compare to Aadi Bioscience?

Summary

How does BioLineRx compare to Dogwood Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLineRx (BLRX) Competitors

BLRX vs. INCR, IMMP, TIL, AADI, and DWTX

How does BioLineRx compare to InterCure?

Which has higher valuation and earnings, BLRX or INCR?

Is BLRX or INCR more profitable?

Do analysts recommend BLRX or INCR?

Which has more volatility and risk, BLRX or INCR?

Do institutionals and insiders hold more shares of BLRX or INCR?

Does the media prefer BLRX or INCR?

Summary

How does BioLineRx compare to Prima BioMed?

Do analysts rate IMMP or BLRX?

Which has more risk & volatility, IMMP or BLRX?

Is IMMP or BLRX more profitable?

Do institutionals & insiders hold more shares of IMMP or BLRX?

Which has better valuation and earnings, IMMP or BLRX?

Does the media favor IMMP or BLRX?

Summary

How does BioLineRx compare to Instil Bio?

Does the media prefer BLRX or TIL?

Do institutionals and insiders hold more shares of BLRX or TIL?

Do analysts rate BLRX or TIL?

Is BLRX or TIL more profitable?

Which has better earnings & valuation, BLRX or TIL?

Which has more risk and volatility, BLRX or TIL?

Summary

How does BioLineRx compare to Aadi Bioscience?

Does the media favor AADI or BLRX?

Do analysts recommend AADI or BLRX?

Do insiders & institutionals hold more shares of AADI or BLRX?

Which has more risk & volatility, AADI or BLRX?

Is AADI or BLRX more profitable?

Which has better valuation and earnings, AADI or BLRX?

Summary

How does BioLineRx compare to Dogwood Therapeutics?

Do analysts recommend BLRX or DWTX?

Is BLRX or DWTX more profitable?

Which has more risk and volatility, BLRX or DWTX?

Does the media prefer BLRX or DWTX?

Do institutionals & insiders believe in BLRX or DWTX?

Which has stronger earnings and valuation, BLRX or DWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools